(It should also be mentioned that previous studies have already observed an inhibitory effect of olaparib on β-catenin expression in various cancer cells [60,61], and in this context, the effect of the PARP inhibitor was implicated in the process of epithelial-to-mesenchymal transition, an important component of cancer cell metastasis). The gene discussed is PARP1; the disease is cancer.